Rense Buijvoets/LinkedIn
May 26, 2026, 14:23
Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?
Rense Buijvoets, Co-owner and Managing director at Sensu, shared a post on LinkedIn:
”1 in 4 deaths worldwide are caused by thrombosis.
What if blood clots could be targeted directly at their source?
TGD001, TargED’s fusion protein in development, binds to blood clots so it can act where it is needed most. By activating plasmin locally, it helps break down VWF and fibrin, allowing the clot to dissolve and blood flow to return.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients